{"analyses":[{"ciLowerLimit":"0.09","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.26","estimateComment":"A larger proportion represents larger benefit.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Proportion Difference - Stratified CMH","paramValue":"0.18","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"107"}],"title":"Responder"},{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"110"}],"title":"Nonresponder"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"description":"RBC transfusion independence is the percentage of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.","groups":[{"description":"Participants received momelotinib plus placebo to match ruxolitinib.\n\nMomelotinib tablets were administered orally once daily at a starting dose of 200 mg.\n\nAdditional available strengths included 100 mg and 150 mg. Placebo to match ruxolitinib tablets were administered orally twice daily.","id":"OG000","title":"Momelotinib (MMB)"},{"description":"Participants received ruxolitinib plus placebo to match momelotinib.\n\nRuxolitinib tablets were administered orally twice daily. The dose ranged from 5 to 20 mg BID and was dependent on platelet count, creatinine clearance, and transaminase levels.\n\nPlacebo to match momelotinib tablets were administered orally once daily.","id":"OG001","title":"Ruxolitinib (RUX)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Week 24","title":"RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)","type":"SECONDARY","unitOfMeasure":"Participants"}